779 A phase 1/2, open label, first-in-human, dose escalation and expansion study of SAR445877 administered as monotherapy in adults with advanced solid tumors
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2023-11-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| _version_ | 1797383514404945920 |
|---|---|
| author | Aung Naing Emiliano Calvo Chen Zhu Martin Gutierrez Elena Garralda Giovanni Abbadessa Helene Guillemin-Paveau Meijing Wu Raymond Perez Marloes van Dongen Ferry Eskens Morgan Finlay Fatima Menas Ozlem Yildirim |
| author_facet | Aung Naing Emiliano Calvo Chen Zhu Martin Gutierrez Elena Garralda Giovanni Abbadessa Helene Guillemin-Paveau Meijing Wu Raymond Perez Marloes van Dongen Ferry Eskens Morgan Finlay Fatima Menas Ozlem Yildirim |
| author_sort | Aung Naing |
| collection | DOAJ |
| first_indexed | 2024-03-08T21:22:04Z |
| format | Article |
| id | doaj.art-3d32fa02092c4fd6a76f63e51aad3bd0 |
| institution | Directory Open Access Journal |
| issn | 2051-1426 |
| language | English |
| last_indexed | 2024-03-08T21:22:04Z |
| publishDate | 2023-11-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj.art-3d32fa02092c4fd6a76f63e51aad3bd02023-12-21T09:00:08ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262023-11-0111Suppl 110.1136/jitc-2023-SITC2023.0779779 A phase 1/2, open label, first-in-human, dose escalation and expansion study of SAR445877 administered as monotherapy in adults with advanced solid tumorsAung Naing0Emiliano Calvo1Chen Zhu2Martin Gutierrez3Elena Garralda4Giovanni Abbadessa5Helene Guillemin-Paveau6Meijing Wu7Raymond Perez8Marloes van Dongen9Ferry Eskens10Morgan Finlay11Fatima Menas12Ozlem Yildirim131The University of Texas MD Anderson Cancer Center, Houston, TX, USASTART Madrid-CIOCC, Centro Integral Oncológico Clara Campal, Madrid, Spain6Sanofi, Cambridge, MA, USA5Hackensack University Medical Center, Hackensack, NJ, USAEarly Drug Development Unit, Vall d’Hebron Institute of Oncology, Barcelona, Spain6Sanofi, Cambridge, MA, USA7Sanofi, Paris, Chilly-Mazarin, France6Sanofi, Cambridge, MA, USA8Sanofi, Pennington, NJ, USA4Antoni Van Leeuwenhoek, Netherlands Cancer Institute, Amsterdam, North Holland, Netherlands5Erasmus University Medical Center, Rotterdam, South Holland, Netherlands1Hackensack Meridian Health, Hackensack, NJ, USA6Sanofi, Madrid, Madrid, Spain7Sanofi, Cambridge, MA, USA |
| spellingShingle | Aung Naing Emiliano Calvo Chen Zhu Martin Gutierrez Elena Garralda Giovanni Abbadessa Helene Guillemin-Paveau Meijing Wu Raymond Perez Marloes van Dongen Ferry Eskens Morgan Finlay Fatima Menas Ozlem Yildirim 779 A phase 1/2, open label, first-in-human, dose escalation and expansion study of SAR445877 administered as monotherapy in adults with advanced solid tumors Journal for ImmunoTherapy of Cancer |
| title | 779 A phase 1/2, open label, first-in-human, dose escalation and expansion study of SAR445877 administered as monotherapy in adults with advanced solid tumors |
| title_full | 779 A phase 1/2, open label, first-in-human, dose escalation and expansion study of SAR445877 administered as monotherapy in adults with advanced solid tumors |
| title_fullStr | 779 A phase 1/2, open label, first-in-human, dose escalation and expansion study of SAR445877 administered as monotherapy in adults with advanced solid tumors |
| title_full_unstemmed | 779 A phase 1/2, open label, first-in-human, dose escalation and expansion study of SAR445877 administered as monotherapy in adults with advanced solid tumors |
| title_short | 779 A phase 1/2, open label, first-in-human, dose escalation and expansion study of SAR445877 administered as monotherapy in adults with advanced solid tumors |
| title_sort | 779 a phase 1 2 open label first in human dose escalation and expansion study of sar445877 administered as monotherapy in adults with advanced solid tumors |
| work_keys_str_mv | AT aungnaing 779aphase12openlabelfirstinhumandoseescalationandexpansionstudyofsar445877administeredasmonotherapyinadultswithadvancedsolidtumors AT emilianocalvo 779aphase12openlabelfirstinhumandoseescalationandexpansionstudyofsar445877administeredasmonotherapyinadultswithadvancedsolidtumors AT chenzhu 779aphase12openlabelfirstinhumandoseescalationandexpansionstudyofsar445877administeredasmonotherapyinadultswithadvancedsolidtumors AT martingutierrez 779aphase12openlabelfirstinhumandoseescalationandexpansionstudyofsar445877administeredasmonotherapyinadultswithadvancedsolidtumors AT elenagarralda 779aphase12openlabelfirstinhumandoseescalationandexpansionstudyofsar445877administeredasmonotherapyinadultswithadvancedsolidtumors AT giovanniabbadessa 779aphase12openlabelfirstinhumandoseescalationandexpansionstudyofsar445877administeredasmonotherapyinadultswithadvancedsolidtumors AT heleneguilleminpaveau 779aphase12openlabelfirstinhumandoseescalationandexpansionstudyofsar445877administeredasmonotherapyinadultswithadvancedsolidtumors AT meijingwu 779aphase12openlabelfirstinhumandoseescalationandexpansionstudyofsar445877administeredasmonotherapyinadultswithadvancedsolidtumors AT raymondperez 779aphase12openlabelfirstinhumandoseescalationandexpansionstudyofsar445877administeredasmonotherapyinadultswithadvancedsolidtumors AT marloesvandongen 779aphase12openlabelfirstinhumandoseescalationandexpansionstudyofsar445877administeredasmonotherapyinadultswithadvancedsolidtumors AT ferryeskens 779aphase12openlabelfirstinhumandoseescalationandexpansionstudyofsar445877administeredasmonotherapyinadultswithadvancedsolidtumors AT morganfinlay 779aphase12openlabelfirstinhumandoseescalationandexpansionstudyofsar445877administeredasmonotherapyinadultswithadvancedsolidtumors AT fatimamenas 779aphase12openlabelfirstinhumandoseescalationandexpansionstudyofsar445877administeredasmonotherapyinadultswithadvancedsolidtumors AT ozlemyildirim 779aphase12openlabelfirstinhumandoseescalationandexpansionstudyofsar445877administeredasmonotherapyinadultswithadvancedsolidtumors |